The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors

Completed

Conditions studied: Gastric Bypass, Depression, Anxiety Disorder

In brief

The morbidly obese frequently present with mood and anxiety disorders, which are often treated with serotonin reuptake inhibitors (SRI) antidepressant drugs. The investigators hypothesized that gastric bypass surgery would decrease the absorption of SRI. The investigators also wished to determine whether a reduction in SRI levels would increase the likelihood of worsening depressive symptoms.

Key facts

Study ID

NCT01317147

Run by

University of Pittsburgh

People needed

12

Starts

2007-08-01

Expected to finish

2010-08-01

Last updated by the study team

2011-03-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to tolerate general anesthesia
• Able to document prior unsuccessful attempts at weight loss under medical supervision during the last 6 months
• Able to provide informed consent
• Cleared for surgery by primary care MD, dietician, and psychiatrist
• SRI treatment specifically for depression for ≥6 wks at constant dose for last 2 out of 6 wks

You may not qualify if…

• pregnancy
• Unwilling or unable to comply with postoperative requirements for diet, supplements, exercise, or followup

Where it is running

• University of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.